FGFR1_HUMAN,F9S,0.828,Altered Disordered interface (Pr = 0.25 | P = 0.02); Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Signal peptide (Pr = 0.12 | P = 1.4e-03), ELME000041|ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,W10P,0.922,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Signal peptide (Pr = 0.09 | P = 2.8e-03), ELME000041|ELME000137,-
FGFR1_HUMAN,A11R,0.872,Altered Disordered interface (Pr = 0.37 | P = 4.8e-03); Altered Signal peptide (Pr = 0.15 | P = 1.6e-03), ELME000041|ELME000106,-
FGFR1_HUMAN,V12S,0.881,Altered Signal peptide (Pr = 0.16 | P = 4.8e-04), ELME000041|ELME000063|ELME000333|ELME000336,-
FGFR1_HUMAN,V14F,0.895,Altered Signal peptide (Pr = 0.21 | P = 2.6e-04), ELME000041|ELME000052|ELME000080|ELME000333|ELME000336,-
FGFR1_HUMAN,T17C,0.800,Altered Signal peptide (Pr = 0.22 | P = 2.2e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05), ELME000052|ELME000053,-
FGFR1_HUMAN,L18Y,0.850,Gain of Loop (Pr = 0.26 | P = 0.05); Altered Signal peptide (Pr = 0.20 | P = 3.1e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.04), ELME000052|ELME000053|ELME000182,-
FGFR1_HUMAN,T20A,0.544,Altered Signal peptide (Pr = 0.22 | P = 2.0e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|PS00005,-
FGFR1_HUMAN,T20M,0.478,-,-,-
FGFR1_HUMAN,A21L,0.848,Altered Signal peptide (Pr = 0.21 | P = 2.2e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053|ELME000136|ELME000159|ELME000313|PS00005,-
FGFR1_HUMAN,R22G,0.670,Loss of ADP-ribosylation at R22 (Pr = 0.27 | P = 7.2e-03); Gain of Loop (Pr = 0.26 | P = 0.05); Altered Signal peptide (Pr = 0.20 | P = 2.7e-04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000005|ELME000053|ELME000136|ELME000155|ELME000159|PS00005,-
FGFR1_HUMAN,P23S,0.612,Altered Signal peptide (Pr = 0.25 | P = 1.4e-04); Loss of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.05); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000005|ELME000053|ELME000063|ELME000064|ELME000136|ELME000155|ELME000159,-
FGFR1_HUMAN,S24T,0.397,-,-,-
FGFR1_HUMAN,L27Y,0.808,Gain of ADP-ribosylation at R22 (Pr = 0.20 | P = 0.03); Altered Transmembrane protein (Pr = 0.13 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q30 (Pr = 0.09 | P = 0.01); Altered Signal peptide (Pr = 0.05 | P = 2.1e-03), ELME000005|ELME000064|ELME000155|ELME000159|ELME000163|ELME000220|PS00006,-
FGFR1_HUMAN,Q30H,0.270,-,-,-
FGFR1_HUMAN,A31T,0.313,-,-,-
FGFR1_HUMAN,Q32L,0.315,-,-,-
FGFR1_HUMAN,F43L,0.126,-,-,-
FGFR1_HUMAN,F43S,0.311,-,-,-
FGFR1_HUMAN,L50P,0.698,Gain of Loop (Pr = 0.31 | P = 3.6e-03); Altered Metal binding (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.27 | P = 0.02); Gain of Disulfide linkage at C55 (Pr = 0.25 | P = 5.2e-03); Altered Transmembrane protein (Pr = 0.16 | P = 0.01), ELME000155|ELME000335,-
FGFR1_HUMAN,R80H,0.655,Gain of Relative solvent accessibility (Pr = 0.26 | P = 0.03); Gain of N-linked glycosylation at N77 (Pr = 0.20 | P = 2.8e-03); Altered Stability (Pr = 0.17 | P = 0.02), ELME000012|ELME000062|ELME000063|ELME000064|ELME000070|ELME000220|PS00001,-
FGFR1_HUMAN,E84A,0.471,-,-,-
FGFR1_HUMAN,V92A,0.176,-,-,-
FGFR1_HUMAN,V92M,0.133,-,-,-
FGFR1_HUMAN,A94S,0.126,-,-,-
FGFR1_HUMAN,S104N,0.181,-,-,-
FGFR1_HUMAN,S105N,0.525,Loss of Intrinsic disorder (Pr = 0.35 | P = 0.05); Loss of B-factor (Pr = 0.26 | P = 0.03); Altered Metal binding (Pr = 0.24 | P = 0.04); Gain of Disulfide linkage at C101 (Pr = 0.20 | P = 0.02); Altered Transmembrane protein (Pr = 0.19 | P = 6.2e-03); Loss of O-linked glycosylation at T103 (Pr = 0.18 | P = 0.03), ELME000053|ELME000063|ELME000136|ELME000159,-
FGFR1_HUMAN,S107L,0.333,-,-,-
FGFR1_HUMAN,T112S,0.115,-,-,-
FGFR1_HUMAN,E126D,0.370,-,-,-
FGFR1_HUMAN,K163N,0.457,-,-,-
FGFR1_HUMAN,E235K,0.304,-,-,-
FGFR1_HUMAN,Y243F,0.610,Altered Transmembrane protein (Pr = 0.30 | P = 1.3e-04); Gain of Relative solvent accessibility (Pr = 0.23 | P = 0.05); Gain of N-linked glycosylation at N240 (Pr = 0.16 | P = 5.4e-03); Loss of Sulfation at Y243 (Pr = 0.02 | P = 0.04), ELME000052|ELME000070|ELME000246|PS00001,-
FGFR1_HUMAN,V247S,0.946,Altered Ordered interface (Pr = 0.33 | P = 8.0e-03); Gain of Intrinsic disorder (Pr = 0.32 | P = 0.03); Altered Transmembrane protein (Pr = 0.27 | P = 5.4e-04); Altered Stability (Pr = 0.23 | P = 9.5e-03); Loss of Sulfation at Y243 (Pr = 0.01 | P = 0.04), ELME000053|ELME000333,-
FGFR1_HUMAN,K265E,0.635,Altered Metal binding (Pr = 0.37 | P = 3.5e-04); Loss of Relative solvent accessibility (Pr = 0.35 | P = 2.4e-03); Altered Ordered interface (Pr = 0.30 | P = 0.02); Gain of Loop (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.20 | P = 5.3e-03); Gain of N-linked glycosylation at N264 (Pr = 0.19 | P = 3.5e-03); Loss of Ubiquitylation at K265 (Pr = 0.16 | P = 0.04), ELME000052|ELME000070|PS00001|PS00008,-
FGFR1_HUMAN,T313H,0.855,Altered Transmembrane protein (Pr = 0.20 | P = 6.0e-03); Gain of N-linked glycosylation at N317 (Pr = 0.19 | P = 3.5e-03), ELME000052,-
FGFR1_HUMAN,M323T,0.674,Altered Transmembrane protein (Pr = 0.34 | P = 2.4e-05); Gain of Loop (Pr = 0.27 | P = 0.04); Gain of Ubiquitylation at K321 (Pr = 0.15 | P = 0.05), ELME000052|ELME000053|ELME000220|ELME000335,-
FGFR1_HUMAN,H327G,0.775,Altered Transmembrane protein (Pr = 0.30 | P = 1.7e-04); Gain of N-linked glycosylation at N330 (Pr = 0.11 | P = 0.01); Altered Stability (Pr = 0.11 | P = 0.04), ELME000122|ELME000137|ELME000334|ELME000335,-
FGFR1_HUMAN,S332T,0.681,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Altered Metal binding (Pr = 0.17 | P = 0.04); Gain of N-linked glycosylation at N330 (Pr = 0.12 | P = 8.3e-03), ELME000070|ELME000122|ELME000137|ELME000146|ELME000220|ELME000334|PS00001|PS00006,-
FGFR1_HUMAN,E334A,0.833,Altered Transmembrane protein (Pr = 0.32 | P = 5.8e-05); Altered Ordered interface (Pr = 0.27 | P = 6.5e-03); Loss of Strand (Pr = 0.27 | P = 0.02); Altered Metal binding (Pr = 0.18 | P = 0.04); Loss of N-linked glycosylation at N330 (Pr = 0.10 | P = 0.01), ELME000070|ELME000122|ELME000137|ELME000321|PS00006,-
FGFR1_HUMAN,E338D,0.665,Altered Metal binding (Pr = 0.29 | P = 0.01); Altered Transmembrane protein (Pr = 0.27 | P = 6.5e-04); Altered Ordered interface (Pr = 0.25 | P = 0.02); Gain of Disulfide linkage at C341 (Pr = 0.23 | P = 0.01); Gain of Sulfation at Y339 (Pr = 0.01 | P = 0.04), None,-
FGFR1_HUMAN,T340C,0.910,Altered Metal binding (Pr = 0.38 | P = 9.4e-03); Altered Transmembrane protein (Pr = 0.36 | P = 1.9e-05); Loss of Loop (Pr = 0.27 | P = 0.04); Altered Ordered interface (Pr = 0.24 | P = 0.03); Loss of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02); Gain of Catalytic site at N345 (Pr = 0.08 | P = 0.05), ELME000120|ELME000182,-
FGFR1_HUMAN,S346Y,0.902,Altered Metal binding (Pr = 0.35 | P = 8.8e-03); Gain of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.25 | P = 1.6e-03); Loss of Disulfide linkage at C341 (Pr = 0.19 | P = 0.02), ELME000053|ELME000083|ELME000120|ELME000182|ELME000239|PS00008,-
FGFR1_HUMAN,I347A,0.886,Altered Stability (Pr = 0.78 | P = 3.6e-04); Altered Transmembrane protein (Pr = 0.29 | P = 2.9e-04); Loss of Strand (Pr = 0.27 | P = 0.03); Loss of Loop (Pr = 0.26 | P = 0.05); Gain of Catalytic site at N345 (Pr = 0.10 | P = 0.04); Gain of GPI-anchor amidation at N345 (Pr = 0.02 | P = 0.02), ELME000053|ELME000085|ELME000239|PS00008,-
FGFR1_HUMAN,S350R,0.845,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Gain of Strand (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.23 | P = 0.05), ELME000053|ELME000063,-
FGFR1_HUMAN,E360R,0.751,Altered Transmembrane protein (Pr = 0.35 | P = 2.4e-05); Gain of Strand (Pr = 0.27 | P = 0.03), ELME000064|ELME000220|ELME000333|PS00006,-
FGFR1_HUMAN,A367T,0.365,-,-,-
FGFR1_HUMAN,A367V,0.451,-,-,-
FGFR1_HUMAN,L373F,0.210,-,-,-
FGFR1_HUMAN,G392V,0.497,-,-,-
FGFR1_HUMAN,G402N,0.127,-,-,-
FGFR1_HUMAN,P483A,0.596,Gain of Helix (Pr = 0.28 | P = 0.03), None,-
FGFR1_HUMAN,I498S,0.715,Gain of Intrinsic disorder (Pr = 0.33 | P = 0.03); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of B-factor (Pr = 0.26 | P = 0.02); Loss of Methylation at K502 (Pr = 0.18 | P = 9.8e-03); Altered Metal binding (Pr = 0.16 | P = 0.02); Altered Stability (Pr = 0.12 | P = 0.03), ELME000085|ELME000239|PS00006|PS00107,-
FGFR1_HUMAN,S518P,0.729,Altered Ordered interface (Pr = 0.33 | P = 9.0e-03); Loss of Relative solvent accessibility (Pr = 0.30 | P = 9.6e-03); Altered DNA binding (Pr = 0.29 | P = 3.9e-03); Gain of Acetylation at K514 (Pr = 0.26 | P = 0.01); Altered Metal binding (Pr = 0.21 | P = 0.03); Loss of Methylation at K517 (Pr = 0.21 | P = 6.0e-03); Loss of Ubiquitylation at K523 (Pr = 0.21 | P = 5.2e-03); Altered Coiled coil (Pr = 0.10 | P = 0.04), ELME000063|ELME000106|ELME000146,-
FGFR1_HUMAN,T521A,0.446,-,-,-
FGFR1_HUMAN,Y572F,0.389,-,-,-
FGFR1_HUMAN,N590H,0.099,-,-,-
FGFR1_HUMAN,P663A,0.855,Altered Ordered interface (Pr = 0.27 | P = 8.3e-03); Altered Transmembrane protein (Pr = 0.10 | P = 0.05), None,-
FGFR1_HUMAN,Q680P,0.917,Loss of Strand (Pr = 0.28 | P = 8.0e-03); Altered Ordered interface (Pr = 0.27 | P = 0.04); Gain of Loop (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.25 | P = 1.2e-03); Altered Metal binding (Pr = 0.19 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q680 (Pr = 0.06 | P = 0.03), ELME000048|ELME000053|ELME000163|ELME000182,-
FGFR1_HUMAN,S681I,0.857,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.7e-03); Altered Metal binding (Pr = 0.17 | P = 0.05); Loss of Pyrrolidone carboxylic acid at Q680 (Pr = 0.05 | P = 0.03); Gain of Sulfation at Y677 (Pr = 0.01 | P = 0.05), ELME000052|ELME000053,-
FGFR1_HUMAN,V683R,0.924,Altered Ordered interface (Pr = 0.35 | P = 4.4e-03); Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Loss of Strand (Pr = 0.26 | P = 0.05); Gain of Allosteric site at W684 (Pr = 0.20 | P = 0.04); Altered Metal binding (Pr = 0.18 | P = 0.04); Gain of Pyrrolidone carboxylic acid at Q680 (Pr = 0.07 | P = 0.02), ELME000053|ELME000062|PS00005,-
FGFR1_HUMAN,Y701N,0.939,Altered Ordered interface (Pr = 0.30 | P = 4.4e-03); Gain of B-factor (Pr = 0.28 | P = 7.8e-03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Catalytic site at Y701 (Pr = 0.11 | P = 0.03), ELME000120|ELME000136|ELME000155|ELME000159,-
FGFR1_HUMAN,M771I,0.102,-,-,-
FGFR1_HUMAN,Y776D,0.577,Gain of Intrinsic disorder (Pr = 0.45 | P = 3.8e-03); Altered Disordered interface (Pr = 0.28 | P = 0.04); Gain of B-factor (Pr = 0.27 | P = 0.01); Gain of Phosphorylation at S777 (Pr = 0.25 | P = 0.03); Loss of Sulfation at Y776 (Pr = 0.12 | P = 2.1e-03), ELME000053|ELME000136|ELME000155|ELME000159|ELME000197,-
FGFR1_HUMAN,L801F,0.309,-,-,-
FGFR1_HUMAN,H810Q,0.128,-,-,-
FGFR1_HUMAN,L814H,0.351,-,-,-
FGFR1_HUMAN,M719R,0.950,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered DNA binding (Pr = 0.17 | P = 0.03); Loss of N-linked glycosylation at N724 (Pr = 0.02 | P = 0.03), ELME000102|ELME000108,-
FGFR1_HUMAN,E467K,0.498,-,-,-
FGFR1_HUMAN,R570W,0.860,Altered Ordered interface (Pr = 0.31 | P = 2.5e-03); Loss of Helix (Pr = 0.28 | P = 0.03), None,-
FGFR1_HUMAN,V795I,0.135,-,-,-
FGFR1_HUMAN,R622G,0.863,Loss of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.26 | P = 9.5e-04); Altered DNA binding (Pr = 0.25 | P = 8.5e-03); Loss of Allosteric site at R627 (Pr = 0.23 | P = 0.03); Loss of Catalytic site at R627 (Pr = 0.12 | P = 0.03), PS00109,-
FGFR1_HUMAN,N117S,0.340,-,-,-
FGFR1_HUMAN,E274G,0.883,Loss of Relative solvent accessibility (Pr = 0.31 | P = 7.3e-03); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Disulfide linkage at C277 (Pr = 0.27 | P = 2.8e-03); Altered Stability (Pr = 0.11 | P = 0.04), ELME000064|PS00006|PS00008,-
FGFR1_HUMAN,G490R,0.949,Gain of Helix (Pr = 0.31 | P = 4.8e-03); Loss of Strand (Pr = 0.29 | P = 4.8e-03), PS00107,-
FGFR1_HUMAN,N330I,0.954,Altered Transmembrane protein (Pr = 0.41 | P = 4.9e-06); Gain of Strand (Pr = 0.26 | P = 0.05); Altered Metal binding (Pr = 0.18 | P = 0.04); Loss of N-linked glycosylation at N330 (Pr = 0.11 | P = 0.01), ELME000070|ELME000122|ELME000137|ELME000333|ELME000334|PS00001,-
FGFR1_HUMAN,R250W,0.864,Altered Transmembrane protein (Pr = 0.32 | P = 8.3e-05); Altered Ordered interface (Pr = 0.27 | P = 0.05), ELME000136|ELME000153|ELME000155|ELME000159,-
FGFR1_HUMAN,K139R,0.283,-,-,-
FGFR1_HUMAN,R148H,0.443,-,-,-
FGFR1_HUMAN,G485R,0.903,, PS00107,-
FGFR1_HUMAN,C277F,0.969,Altered Metal binding (Pr = 0.78 | P = 5.7e-04); Loss of Disulfide linkage at C277 (Pr = 0.58 | P = 2.9e-04); Altered Ordered interface (Pr = 0.28 | P = 0.05); Gain of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Altered Transmembrane protein (Pr = 0.24 | P = 1.7e-03), None,-
FGFR1_HUMAN,P483S,0.688,, ELME000064|ELME000336|PS00006,-
FGFR1_HUMAN,C381R,0.892,Gain of Helix (Pr = 0.28 | P = 0.02); Gain of ADP-ribosylation at C381 (Pr = 0.22 | P = 0.02), ELME000182,-
FGFR1_HUMAN,R470L,0.722,, None,-
FGFR1_HUMAN,R475Q,0.688,, ELME000331,-
FGFR1_HUMAN,P745S,0.848,Loss of Loop (Pr = 0.28 | P = 0.02); Altered DNA binding (Pr = 0.16 | P = 0.04), ELME000053|ELME000062|ELME000063|ELME000202,-
FGFR1_HUMAN,A361P,0.861,Altered Transmembrane protein (Pr = 0.27 | P = 7.2e-04), ELME000117|ELME000155|ELME000220,-
FGFR1_HUMAN,R718G,0.940,Altered DNA binding (Pr = 0.19 | P = 0.02), None,-
FGFR1_HUMAN,V607M,0.827,Gain of Helix (Pr = 0.27 | P = 0.03); Altered Ordered interface (Pr = 0.26 | P = 0.01), None,-
FGFR1_HUMAN,G703S,0.811,Altered Ordered interface (Pr = 0.24 | P = 0.05); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Catalytic site at Y701 (Pr = 0.11 | P = 0.03), ELME000120|ELME000133|ELME000155|ELME000239,-
FGFR1_HUMAN,L630P,0.974,Gain of Relative solvent accessibility (Pr = 0.35 | P = 1.5e-03); Altered Ordered interface (Pr = 0.34 | P = 5.3e-03); Altered DNA binding (Pr = 0.30 | P = 1.6e-03); Gain of Allosteric site at R627 (Pr = 0.29 | P = 2.9e-03); Altered Metal binding (Pr = 0.27 | P = 0.02); Gain of Strand (Pr = 0.26 | P = 0.05); Altered Transmembrane protein (Pr = 0.24 | P = 1.8e-03); Altered Stability (Pr = 0.23 | P = 9.5e-03); Loss of Catalytic site at R627 (Pr = 0.12 | P = 0.03), ELME000146|ELME000333|PS00109,-
FGFR1_HUMAN,G703R,0.914,Altered Ordered interface (Pr = 0.30 | P = 0.02); Altered Transmembrane protein (Pr = 0.14 | P = 0.02); Loss of Catalytic site at Y701 (Pr = 0.12 | P = 0.03), ELME000120|ELME000133|ELME000155,-
FGFR1_HUMAN,P283R,0.803,Altered Transmembrane protein (Pr = 0.26 | P = 1.2e-03); Altered Metal binding (Pr = 0.14 | P = 0.05), ELME000173|PS00005,-
FGFR1_HUMAN,E692G,0.943,Altered Ordered interface (Pr = 0.26 | P = 0.01); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000053,-
FGFR1_HUMAN,M1K,0.957,Altered Disordered interface (Pr = 0.45 | P = 2.3e-03); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03); Altered Stability (Pr = 0.11 | P = 0.04); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000351|ELME000355,-
FGFR1_HUMAN,W2C,0.732,Altered Ordered interface (Pr = 0.24 | P = 0.04); Altered Disordered interface (Pr = 0.24 | P = 0.03); Altered Signal peptide (Pr = 0.12 | P = 1.5e-03); Loss of N-terminal acetylation at M1 (Pr = 0.02 | P = 6.1e-03), ELME000354|ELME000355,-
FGFR1_HUMAN,L7I,0.558,Altered Disordered interface (Pr = 0.20 | P = 0.03); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03), ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,L7M,0.580,Altered Disordered interface (Pr = 0.24 | P = 0.02); Altered Signal peptide (Pr = 0.19 | P = 7.2e-04), ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,L8H,0.915,Altered Disordered interface (Pr = 0.20 | P = 0.03); Altered Signal peptide (Pr = 0.11 | P = 1.7e-03), ELME000106|ELME000137|ELME000146,-
FGFR1_HUMAN,L8I,0.520,Altered Disordered interface (Pr = 0.18 | P = 0.04); Altered Signal peptide (Pr = 0.11 | P = 1.6e-03), ELME000106|ELME000137|ELME000146,-
